<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643784</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-14-10028</org_study_id>
    <nct_id>NCT02643784</nct_id>
  </id_info>
  <brief_title>Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke</brief_title>
  <acronym>AIS</acronym>
  <official_title>Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, randomized, open-label, 2-arm, parallel-group study exploring the&#xD;
      efficacy of rosuvastatin (20mg/day) in patients with acute ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 90-day, explanatory; randomized; open-label, 2-arm; parallel group with blinded&#xD;
      outcome evaluation study exploring the efficacy and study of early rosuvastatin 20 mg/d&#xD;
      treatment in acute ischemic patients with stroke onset in 24 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent changes in infarction volumes measured by MRI on the 14th day compared with the baseline of the stroke</measure>
    <time_frame>0-14d</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute changes in infarction volumes measured by MRI on the 14th day compared with the baseline of the stroke</measure>
    <time_frame>0-14d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients whose infarction volume reduced on the 14th day compared with the baseline of the stroke</measure>
    <time_frame>0-14d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The neurological outcomes measured by NIHSS (14,90 days), compared between statin group and standard group</measure>
    <time_frame>14-90d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The functional outcome measured by modified Rankin Scale (14,90 days), compared between statin group and standard group</measure>
    <time_frame>14-90d</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of the new-onset infarct assessed by MRI from baseline to 14th day, compared between statin group and standard group</measure>
    <time_frame>0-14d</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ischemic</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin study drug will be supplied in tablets (10 mg), assigned dose to be taken orally, once daily by subjects randomized to receive rosuvastatin 20 mg(take rosuvastatin until 14th day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group(don't take rosuvastatin until 14th day), as directed by the study physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.&#xD;
Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day.</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>RSV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Randomized Treatment Period (Day 1 through Day 14):&#xD;
No treatment of rosuvastatin for control group. Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day.</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 45 to 75 years old patients;&#xD;
&#xD;
          2. Stroke involving the vascular territory of the middle cerebral artery (MCA) as judged&#xD;
             by clinical and MRI evidences;&#xD;
&#xD;
          3. Time from symptom onset to take the study assigned medication is within 24 hours;&#xD;
&#xD;
          4. Statin naïve or discontinued at least 3 month before stroke onset;&#xD;
&#xD;
          5. First ever stroke or mild sequelae (with modified Rankin Score 0-1) before the index&#xD;
             event;&#xD;
&#xD;
          6. Moderate neurological deficit with baseline NIHSS scoring from 4-20;&#xD;
&#xD;
          7. MRI scans （T1W1、T2W2、T2Flair、DWI、SWI）accomplished from 12 to 48 hours after the onset;&#xD;
&#xD;
          8. Consent form signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Any of the following is regarded as a criterion for exclusion from the study:&#xD;
&#xD;
          1. Stroke involving the vascular territory of the vertebrobasilar artery as judged by&#xD;
             clinical and MRI evidences;&#xD;
&#xD;
          2. Hemorrhagic transformation or intracranial hemorrhage on baseline MRI. MRI performed&#xD;
             between 12-48 hours after the onset, if MRI provides evidences which met with the&#xD;
             exclusion criteria, the patients will be excluded from the study;&#xD;
&#xD;
          3. Any circumstances under which MRI scans can't be performed;&#xD;
&#xD;
          4. Evidences suggesting cardiogenic stroke such as atrial fibrillation, acute coronary&#xD;
             syndrome, patent foramen ovale , etc;&#xD;
&#xD;
          5. Comatose with NIHSS 1a&gt;1;&#xD;
&#xD;
          6. Medical or psychiatric conditions such as severe hepatic or renal dysfunction, heart&#xD;
             failure, malignancy, major depression, dementia, alcohol or drug abuse;&#xD;
&#xD;
          7. Suitable for rt-Plasminogen Activator thrombolysis treatment;&#xD;
&#xD;
          8. Receiving medication with possible neuroprotective functions after stroke onset;&#xD;
&#xD;
          9. Currently take steroids therapy;&#xD;
&#xD;
         10. Diagnosed with malignancy within 5 years;&#xD;
&#xD;
         11. Patients with myopathy or serum creatine kinase &gt; 3 times the upper limit of normal&#xD;
             not caused by myocardial injury;&#xD;
&#xD;
         12. Severe renal function damage (eGFR&lt;30);&#xD;
&#xD;
         13. Concurrent use ciclosporin;&#xD;
&#xD;
         14. A history of hypersensitivity of statins and other severe complication;&#xD;
&#xD;
         15. Child-bearing women ;&#xD;
&#xD;
         16. Patients who are or may be pregnant;&#xD;
&#xD;
         17. Other conditions under which patients not pertinent to attend the study as judged by&#xD;
             the investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

